CGT Global

Executive Summary

CGT Global is a US-based CDMO specializing in cell and gene therapies, providing end-to-end services from preclinical development to commercial-scale manufacturing. Founded in 2018 and headquartered in Philadelphia, the company supports biotech and pharma clients in bringing complex advanced therapies to market. As the cell and gene therapy market expands, driven by increasing approvals and pipeline growth, CGT Global is positioned to benefit from rising demand for specialized manufacturing capacity. Its focus on quality, regulatory expertise, and scalability makes it a key partner for developers seeking reliable outsourced production. While the CDMO space is competitive, CGT Global's niche specialization and recent capacity investments could drive revenue growth. The company's success hinges on securing long-term client contracts, expanding its facility footprint, and achieving operational efficiencies. Overall, CGT Global presents a compelling opportunity in the expanding advanced therapy manufacturing sector, though execution risks and competition remain.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership or multi-year manufacturing agreement with a top-20 biopharma60% success
• Q4 2026Completion of manufacturing capacity expansion at Philadelphia facility75% success
• Q1 2027FDA approval of a client's cell or gene therapy that relies on CGT Global's manufacturing40% success